TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00436930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor cell vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study: NCT04260035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasoactive Intestinal Polypeptide (VIP)
Description: 20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
Study: NCT00436930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given subcutaneously
Study: NCT02749669

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative research
Description: Semi-structured Interviews
Study: NCT04545359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alpha-based neurofeedback
Description: Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions.
Study: NCT03252457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
Study: NCT02450058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 600 mg/m2 intravenously on day 1, every 21 days for six cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 60 mg/m2 intravenously on day 1, every 21 days for six cyles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenously on day 1, every 21 days for six cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 90 mg/m2 on day 1, every 21 days for four cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
Study: NCT02979132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eisensulfat LOMAPHARM 50 mg
Description: oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject(R)
Description: Single-dose Ferinject(R) administration

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron fortified biscuits
Description: consumption of an iron-fortfied biscuit every morning for 90 days
Study: NCT04231292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD01
Description: RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD01
Description: RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD01
Description: RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD01
Description: RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD01
Description: RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Erythropoiesis Injection (CHO cell)
Description: rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Human Erythropoiesis Injection (CHO cell)
Description: rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02489864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Study: NCT03433404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Mobilization
Description: The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Massage
Description: For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
Study: NCT03473002

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SeVRSV Vaccine
Description: Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
Study: NCT04545359

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions.
Study: NCT04350346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motilitone
Description: 1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gasmotin
Description: 1. Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~2. Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~3. Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle
Study: NCT02779712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic conditioning
Description: 1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
Study: NCT04553406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720
Description: Capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label Standard of Care
Description: Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days.
Study: NCT03535987

Intervention type: DEVICE
Intervention: myocardial PET imaging
Description: using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
Study: NCT02409797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexion-Distraction (non-thrust) spinal manipulation
Description: Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
Study: NCT01528293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiVAC System
Description: The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression therapy
Description: Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: Compression therapy
Description: Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
Study: NCT01675739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short message service of mobile phone (SMS)
Description: In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol (PEG)
Description: No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol (PEG)
Description: No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS
Study: NCT03540160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Serlopitant Tablets
Description: Serlopitant Tablets
Study: NCT03505008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Route of Administration: Oral
Study: NCT02800954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marow samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marow samples
Study: NCT02637128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Description: Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Description: Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
Study: NCT01234818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena (LNG-IUS)
Description: * General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
Study: NCT01920555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Dose of Ketamine will be 0.1 mg/kg - one single infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Dose of Ketamine will be 0.2 mg/kg - one single infusion
Study: NCT03090217

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care (SC)
Description: 1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
Study: NCT03748264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant but will continuously be available to site staff personnel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreamMapper Application
Description: The DreamMapper application condition will receive the site's therapy initiation standard of care and will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreamMapper Application with Therapist Assist
Description: The DreamMapper with Therapist Assist will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, their Philips Respironics mask and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously.
Study: NCT04261920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huangqi Guizhi Wuwu decoction
Description: The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huangqi Guizhi Wuwu decoction
Description: The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).
Study: NCT04572542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2
Study: NCT04089176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
Study: NCT00664521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
Study: NCT03818997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Patient will receive DKN-01 300 mg IV every 2 weeks
Study: NCT01920555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Dose of Ketamine will be 0.5 mg/kg - one single infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Dose of Ketamine will be 1.0 mg/kg - one single infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Midazolam
Description: Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
Study: NCT01123239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached Care
Description: Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Education
Description: Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
Study: NCT01323842

Intervention type: PROCEDURE
Intervention: EDTU
Description: bedside ultrasound imaging by the treating emergency physician
Study: NCT03415100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK cells targeting NKG2D ligands
Description: The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.